Does semaglutide help with PCOS?

Dr. Linda's take

If you have PCOS and you've been hearing about semaglutide everywhere, you've probably felt two things at once: curiosity, and a little bit of whiplash. Search "PCOS treatment" online and most of what surfaces is generic weight-loss content that was never built for a hormonal condition like this one. That gap is worth naming, because PCOS is not simply a weight issue. It is a metabolic and reproductive condition, and research on this specific use is newer and smaller than the research behind semaglutide's approved uses. My goal here is not to tell you what to take. It is to walk you through what the science actually shows right now, so that when you sit down with a clinician, you are asking sharper questions and hearing sharper answers.

What is PCOS, exactly?

Polycystic ovary syndrome is a hormonal condition that affects how the ovaries work. Clinicians typically diagnose PCOS when a person has at least two of three features: irregular or absent ovulation, higher than typical levels of androgens or visible signs of them such as acne or extra hair growth, and ovaries containing multiple small follicles on imaging. Insulin resistance is common in PCOS and is closely tied to many of its symptoms, including irregular cycles and weight changes. Because PCOS touches metabolism, fertility, and appearance all at once, it rarely responds to a single, one-size-fits-all approach, which is part of why researchers have started looking at newer treatment classes for PCOS as well.

Most of the mainstream weight-loss content built around these medications was not written with PCOS in mind, and it tends to frame them purely around appearance. That framing misses what is actually being studied in this population: not thinness, but whether supporting insulin sensitivity and weight change can also ease the downstream symptoms, cycle irregularity, and metabolic strain that come with PCOS. That is a meaningfully different question, and it deserves a different kind of answer than a generic weight-loss article gives you.

Why are researchers interested in this medication class for PCOS?

Semaglutide belongs to a class of medicines called GLP-1 receptor agonists, a group that also includes tirzepatide and that was originally developed for diabetes before some members were approved for chronic weight management. Because insulin resistance sits at the center of so much PCOS physiology, researchers have hypothesized that a medication class built around supporting insulin sensitivity and weight change could ripple outward into other PCOS symptoms, including cycle regularity. That hypothesis is now being tested directly, rather than assumed, and the studies below are where that testing currently stands.

How is semaglutide being studied for PCOS?

Semaglutide is FDA-approved for chronic weight management and, in certain patients with obesity or overweight and established heart disease, for reducing cardiovascular risk. Semaglutide is not FDA-approved to treat PCOS specifically, so using it to address PCOS symptoms is currently considered off-label, and dedicated PCOS trials are still underway to build out that evidence base.

A handful of trials have now tested semaglutide directly in women with PCOS. In one 16-week randomized, controlled trial of 100 overweight or obese women with PCOS, the group combining semaglutide with metformin lost an average of about 6 kg, compared with about 2.25 kg in the metformin-only group. Menstrual cycles became regular again in about 73% of the combination group, compared with about 42% of the metformin-only group, over that same 16 weeks. Across a 24-week follow-up period, natural pregnancy occurred in 35% of the combination group compared with 15% of the metformin-only group, though total pregnancy rates including fertility treatment were similar between the two groups.

Looking more broadly across studies of this medication class in PCOS, not semaglutide alone, researchers have reported reductions in BMI, waist circumference, and markers of insulin resistance, alongside shifts in reproductive hormones such as sex hormone-binding globulin and free testosterone. Investigators describe this medication class as a promising direction for obesity-related PCOS, while also cautioning that most existing trials are small and short, and not yet sized or long enough to settle questions about durability or long-term outcomes.

What are the safety considerations?

Semaglutide's FDA prescribing information carries a boxed warning: in rodent studies, semaglutide caused thyroid C-cell tumors, and whether it does the same in humans is not known. Because of that finding, semaglutide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. In the PCOS-specific research, the most commonly reported side effects were gastrointestinal, including nausea, vomiting, and diarrhea, and gastrointestinal symptoms were also the leading reason participants stopped the medication.

None of this is a reason to rule semaglutide in or out for you personally. It is context for the conversation you have with a licensed clinician who knows your full history, including your thyroid and family history.

What should you ask your clinician?

If you want a structured way to start that conversation, Body Good Studio's quiz is built to map your symptoms to a starting point before you talk with a clinician.

Frequently asked questions

Is semaglutide FDA-approved for PCOS?

No. Semaglutide is FDA-approved for chronic weight management and, in some patients, for reducing cardiovascular risk. Semaglutide is not FDA-approved for PCOS specifically, so its use for PCOS symptoms is considered off-label.

Does semaglutide address the underlying hormonal drivers of PCOS?

PCOS is a hormonal and metabolic condition. Semaglutide's studied effects in PCOS trials are on weight, insulin resistance, and related markers like menstrual regularity, not a direct treatment of the underlying hormonal drivers of PCOS.

How much weight loss have PCOS-specific trials shown?

In one 16-week randomized trial, women combining semaglutide with metformin lost an average of about 6 kg, versus about 2.25 kg with metformin alone. That was a short trial in a specific population, so individual results vary and longer-term data are still limited.

What are the most common side effects reported in these studies?

Gastrointestinal effects, especially nausea, vomiting, and diarrhea, were the most frequently reported side effects in this medication class among PCOS trial participants, and they were also the leading reason participants stopped treatment.

Is semaglutide appropriate for someone trying to get pregnant?

This is exactly the kind of question to bring to a clinician, since semaglutide's labeling and the PCOS-fertility research base are both still evolving, and a licensed clinician can walk you through current guidance for your specific situation.

References

1. National Institute of Child Health and Human Development (NICHD) (2026). About Polycystic Ovary Syndrome (PCOS). National Institutes of Health. https://www.nichd.nih.gov/health/topics/pcos (Accessed 2026-07-12).
2. Bednarz K, Kowalczyk K, Cwynar M, Czapla D, Czarkowski W, Kmita D, Nowak A, Madej P (2022). The Role of GLP-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. International Journal of Molecular Sciences, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC9029608/ (Accessed 2026-07-12).
3. U.S. Food and Drug Administration / Novo Nordisk (2025). WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564 (Accessed 2026-07-12).
4. Chen H, Lei X, Yang Z, Xu Y, Liu D, Wang C, Du H (2025). Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reproductive Biology and Endocrinology, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC12297736/ (Accessed 2026-07-12).
5. Machado MF, Shunk T, Hansen G, Harvey C, Fulford B, Hauf S, Schuh O, Kaldas M, Arcaroli E, Ortiz J, De Gaetano J (2024). Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review. Cureus, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC11389649/ (Accessed 2026-07-12).